Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8270 · Every Dollar Counts Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

26 U.S.C. § 9826 Counting out-of-pocket expenditures for certain drugs towards a deductible and out-of-pocket maximum New section

+2 −0Shown
More for 26 U.S.C. § 9826
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:9826. Counting out-of-pocket expenditures for certain drugs towards a deductible and out-of-pocket maximum A group health plan shall, in the case of an individual enrolled under such plan who elects to purchase a drug for which benefits are available under such plan without applying such benefits, count any out-of-pocket expenditures incurred by such individual with respect to such drug towards any deductible and out-of-pocket maximum that would have applied had such individual applied such benefits..

    The section already has a provision under this letter or number, so it would have two.

The Code already has a 26 U.S.C. § 9826, a different section added since this bill was written, so this would be a second section under that number.

§ 9826

WhereMarkThe Code nowMarkAs the bill would leave it
§ 9826. [inserted: Counting out-of-pocket expenditures for certain drugs towards a deductible and out-of-pocket maximum]
[inserted: A group health plan shall, in the case of an individual enrolled under such plan who elects to purchase a drug for which benefits are available under such plan without applying such benefits, count any out-of-pocket expenditures incurred by such individual with respect to such drug towards any deductible and out-of-pocket maximum that would have applied had such individual applied such benefits.]

42 U.S.C. § 1396r–8 Payment for covered outpatient drugs

+8 −4Shown
More for 42 U.S.C. § 1396r–8
Read § 1396r–8Only this section
6 changes the bill asks for here, 6 carried out
  1. Carried out:

    in subclause (IV), by striking and at the end;

  2. Carried out:

    in subclause (V), by striking the period at the end and inserting ; and; and

  3. Carried out:

    by adding at the end the following new subclause:(VI) shall exclude any reduction in price with respect to an individual purchasing such drug without applying any benefits under a group health plan (as defined in section 2791 of the Public Health Service Act), group or individual health insurance coverage (as so defined), or a …

  4. Carried out:

    in subclause (VII), by striking and at the end;

  5. Carried out:

    in subclause (VIII), by striking the period at the end and inserting ; and; and

  6. Carried out:

    by adding at the end the following new subclause:(IX) any reduction in price with respect to an individual purchasing such drug without applying any benefits under a group health plan (as defined in section 2791 of the Public Health Service Act), group or individual health insurance coverage (as so defined), or a Federal …

§ 1396r–8(c)(1)Basic rebate for single source drugs and innovator multiple source drugs(C)–(D)

Start of § 1396r–8 to (c)(1)(C)(ii)(II) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(C)(ii)(III)(III) (III)
shall not take into account prices that are merely nominal in amount3shall not take into account prices that are merely nominal in amount3
(C)(ii)(IV)(IV) (IV)
in the case of a manufacturer that approves, allows, or otherwise permits any other drug of the manufacturer to be sold under a new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], shall be inclusive of the lowest price for such authorized drug available from the manufacturer during the rebate period to any manufacturer, wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, excluding those prices described in subclauses (I) through (IV) of clause (i);[struck: and]in the case of a manufacturer that approves, allows, or otherwise permits any other drug of the manufacturer to be sold under a new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], shall be inclusive of the lowest price for such authorized drug available from the manufacturer during the rebate period to any manufacturer, wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, excluding those prices described in subclauses (I) through (IV) of clause (i);
(C)(ii)(V)(V) (V)
in the case of a rebate period and a covered outpatient drug that is a selected drug (as referred to in section 1320f–1(c) of this title) during such rebate period, shall be inclusive of the maximum fair price (as defined in section 1320f(c)(3) of this title) for such drug with respect to such period[struck: .]in the case of a rebate period and a covered outpatient drug that is a selected drug (as referred to in section 1320f–1(c) of this title) during such rebate period, shall be inclusive of the maximum fair price (as defined in section 1320f(c)(3) of this title) for such drug with respect to such period[inserted: ; and]
(C)(ii)(VI)(VI) [inserted: ]
[inserted: shall exclude any reduction in price with respect to an individual purchasing such drug without applying any benefits under a group health plan (as defined in section 2791 of the Public Health Service Act), group or individual health insurance coverage (as so defined), or a Federal health care program (as defined in section 1128B but including the program established under chapter 89 of title 5, United States Code).]
(C)(iii)(iii) Application of auditing and recordkeeping requirements(iii) Application of auditing and recordkeeping requirements
With respect to a covered entity described in section 256b(a)(4)(L) of this title, any drug purchased for inpatient use shall be subject to the auditing and recordkeeping requirements described in section 256b(a)(5)(C) of this title.With respect to a covered entity described in section 256b(a)(4)(L) of this title, any drug purchased for inpatient use shall be subject to the auditing and recordkeeping requirements described in section 256b(a)(5)(C) of this title.
(D)(D) Limitation on sales at a nominal price(D) Limitation on sales at a nominal price

§ 1396r–8(k)(1)Average manufacturer price(B)–(C)

(c)(1)(D)(i)–(k)(1)(B)(i) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(B)(i)(VI)(VI) (VI)
any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI;any reduction in price paid during the rebate period to the manufacturer for a drug by reason of application of part E of subchapter XI;
(B)(i)(VII)(VII) (VII)
rebates paid by manufacturers under section 1395w–3a(i) of this title;[struck: and]rebates paid by manufacturers under section 1395w–3a(i) of this title;
(B)(i)(VIII)(VIII) (VIII)
rebates paid by manufacturers under section 1395w–114b of this title[struck: .]rebates paid by manufacturers under section 1395w–114b of this title[inserted: ; and]
(B)(i)(IX)(IX) [inserted: ]
[inserted: any reduction in price with respect to an individual purchasing such drug without applying any benefits under a group health plan (as defined in section 2791 of the Public Health Service Act), group or individual health insurance coverage (as so defined), or a Federal health care program (as defined in section 1128B but including the program established under chapter 89 of title 5, United States Code).]
(B)(ii)(ii) Inclusion of other discounts and payments(ii) Inclusion of other discounts and payments
Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug.Notwithstanding clause (i), any other discounts, rebates, payments, or other financial transactions that are received by, paid by, or passed through to, retail community pharmacies shall be included in the average manufacturer price for a covered outpatient drug.
(C)(C) Exclusion of section 505(c) drugs(C) Exclusion of section 505(c) drugs
In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies.In the case of a manufacturer that approves, allows, or otherwise permits any drug of the manufacturer to be sold under the manufacturer’s new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], such term shall be exclusive of the average price paid for such drug by wholesalers for drugs distributed to retail community pharmacies.

Rest of § 1396r–8 unchanged

Step through the changes